The Journal of Affective Disorders is a premier publication in the field of Clinical Psychology and Psychiatry and Mental Health, published by Elsevier. With an impressive impact factor and a consistent ranking in the Q1 category—12th in Clinical Psychology and 40th in Psychiatry and Mental Health—the journal serves as a critical platform for advancing research on affective disorders since its inception in 1979. The journal’s scope encompasses a wide range of topics related to mood disorders, providing researchers, professionals, and students with the latest findings, theoretical developments, and clinical insights. Despite being a non-open-access journal, subscribers benefit from comprehensive access to high-quality, peer-reviewed articles that inform clinical practice and enrich academic discourse. With its commitment to fostering scientific progress, The Journal of Affective Disorders remains instrumental in shaping the future of mental health research and practice.

Psychiatry and Clinical Psychopharmacology, an open-access journal published by AVES since 2017, is dedicated to advancing the fields of psychiatric medicine and psychopharmacology. With an ISSN of 2475-0573 and an E-ISSN of 2475-0581, this journal aims to provide a platform for disseminating innovative research and clinical findings relevant to mental health professionals and researchers. Although it currently holds a Q3 ranking in Pharmacology (medical) and a Q4 ranking in Psychiatry and Mental Health according to the 2023 category quartiles, the journal has established itself as a significant contributor to evolving discussions in these critical fields. Based in the United Kingdom, the journal encompasses diverse topics, ranging from pharmacological treatments to novel therapeutic approaches in psychiatry, thereby appealing to a broad audience of clinicians, scientists, and students. The open-access model ensures that all research is readily available, fostering an environment of collaboration and knowledge-sharing as the journal converges until 2024 to encompass the latest advancements in both pharmacology and clinical psychopharmacology.

Annals of General Psychiatry is a leading open-access journal published by BMC, dedicated to advancing the field of psychiatry and mental health. Since its inception in 2005, the journal has provided a robust platform for researchers to disseminate peer-reviewed clinical and experimental studies, case reports, and reviews that address the broad spectrum of psychiatric disorders. With an impressive Q1 ranking in Psychiatry and Mental Health for 2023, and a notable Scopus rank of #128 out of 567 in its category, the journal plays a pivotal role in disseminating high-quality, impactful research within the global scientific community. The open access model guarantees wide visibility and accessibility of research findings, ensuring that professionals, students, and policymakers can utilize the latest advancements in the psychiatric field. The journal's presence from 2002 to 2024 further demonstrates its commitment to contributing valuable insights that are relevant to contemporary challenges in mental health.

JAMA Psychiatry, published by the American Medical Association, stands as a leading peer-reviewed journal in the fields of psychiatry and mental health, featuring an impressive impact factor that reflects its significance in advancing research and clinical practice. With an ISSN of 2168-622X and an E-ISSN of 2168-6238, this journal operates on a comprehensive access model that allows for the dissemination of vital research findings to a global audience. Since its inception in 2013, JAMA Psychiatry has consistently ranked in the top quartile (Q1) in both the Medicine (miscellaneous) and Psychiatry and Mental Health categories, with a remarkable Scopus rank of #4 out of 567, placing it in the 99th percentile. Addressed from its headquarters in Chicago, Illinois, the journal's objectives encompass the publication of original clinical research, innovative treatment strategies, and insightful reviews that enrich the understanding of psychiatric disorders. By bridging the gap between research and real-world application, JAMA Psychiatry remains an essential resource for researchers, clinicians, and students dedicated to improving mental health outcomes.

Adolescent Psychiatry, an esteemed publication by Bentham Science Publishers, focuses on the intricate and evolving field of adolescent mental health, covering a broad spectrum of topics relevant to both psychiatry and pediatrics. With its ISSN of 2210-6766 and E-ISSN of 2210-6774, this journal contributes significantly to its fields through rigorous research articles, clinical studies, and comprehensive reviews that enhance our understanding of adolescent psychological well-being. Operating out of the United Arab Emirates, this journal's impact is reflected in its Scopus rankings, placing it within the Q3 category of Pediatrics and Q4 in Psychiatry and Mental Health for 2023. Although not an open-access journal, it remains a vital resource for researchers, clinicians, and students seeking to advance their knowledge and practice regarding mental health issues in adolescents. With converged publication years from 2014 to 2015 and from 2019 to 2024, it continues to strive for excellence in publishing high-quality research that tackles contemporary challenges in adolescent psychiatry.

Neuropsychopharmacology Reports is a leading open-access journal published by WILEY, dedicated to advancing the fields of clinical psychology, pharmacology, psychiatry, and mental health. Established in 2018, the journal aims to disseminate high-quality research findings, critical reviews, and innovative methodologies that elucidate the complexities of neuropsychopharmacology in enhancing mental health outcomes. With an impressive impact indicated by its Q2 rankings in several categories including Clinical Psychology and Pharmacology (medical) as of 2023, Neuropsychopharmacology Reports stands out as a vital resource for researchers, professionals, and students keen on exploring the interplay between pharmacological interventions and psychological well-being. The journal’s open-access nature ensures that critical advancements in this rapidly evolving field are readily available to a global audience, fostering collaboration and discourse among scholars and practitioners alike. Building on its indexed status with Scopus, the journal is positioned as a noteworthy contributor to ongoing discussions and developments in psychiatry and medical pharmacology.

Minerva Psychiatry is an innovative open-access journal published by EDIZIONI MINERVA MEDICA, focusing on the field of psychiatry and mental health. Launched in 2021, the journal aims to advance understanding and research in this critical area of medicine, serving as a platform for the dissemination of original research, clinical trials, and reviews that contribute to the improvement of mental health practices globally. With an ISSN of 2724-6612 and E-ISSN 2724-6108, this journal is situated in Italy and addresses a wide array of topics relevant to both practitioners and researchers in psychiatry. While the journal is currently ranked Q4 in its category, it seeks to enhance its impact by fostering high-quality submissions that address contemporary issues in mental health. Interested authors and readers can explore its publications through open access, encouraging a collective effort to elevate the standards and accessibility of psychiatric knowledge. With its commitment to nurturing a robust dialogue in the field, Minerva Psychiatry is positioned to become a valuable resource for those dedicated to mental health research and practice.

Annals of Clinical Psychiatry, published by QUADRANT HEALTHCOM INC, is a leading journal in the fields of Medicine and Psychiatry & Mental Health. With its longstanding commitment to advancing clinical knowledge since 1989, this esteemed journal contributes invaluable insights into current psychiatric practices and mental health research. The journal is recognized in the Scopus ranking with a position in the 34th percentile, reflective of its focused scope and substantial academic contributions. While access to the journal is tailored for professionals and researchers, the absence of Open Access highlights the journal's dedication to maintaining quality and rigorous peer-reviewed standards. As part of the Q3 quartile for both Medicine and Psychiatry categories in 2023, Annals of Clinical Psychiatry serves as an essential resource for those dedicated to improving mental health outcomes, making it a vital platform for practitioners, researchers, and students alike. Situated in Parsippany, New Jersey, the journal remains a pivotal entity that fosters scholarly dialogue and exploration in clinical psychiatry.

Current Psychiatry Reports, published by Springer, is a premier academic journal dedicated to the dissemination of cutting-edge research in the field of psychiatry and mental health. With a significant impact factor reflecting its esteemed position at Q1 in Psychiatry, this journal ranks an impressive #35 out of 567 in its category, placing it within the 93rd percentile of psychiatric publications as per Scopus metrics. Since its inception in 1996, it has provided a vital platform for clinicians, researchers, and students to explore and discuss contemporary psychiatric issues, advancements, and methodologies. While Current Psychiatry Reports is a subscription-based journal, its robust scholarly contributions are invaluable for practitioners and scholars looking to stay abreast of developments and empirical studies that shape the field. Based in the United States, at ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY 10004, it remains an authoritative source for evidence-based insights that guide both research and clinical practice in mental health.

Welcome to the Spanish Journal of Psychiatry and Mental Health, a leading platform for innovative research and discourse in the fields of psychiatry and mental health. Published by ELSEVIER ESPANA SLU, this peer-reviewed journal serves as a critical resource for clinicians, researchers, and students dedicated to advancing understanding and treatment of mental health disorders. With a commendable ranking of #54 out of 567 in the Psychiatry and Mental Health category according to Scopus, it proudly positions itself in the 90th percentile, reinforcing its significance within the academic community. As an open-access journal, it aims to disseminate high-quality research to a global audience, promoting collaboration and knowledge sharing among mental health professionals. The journal's dynamic publication schedule, covering Converged Years from 2023 to 2024, ensures that it remains at the forefront of mental health scholarship. We invite you to explore the latest findings, engage with thought-provoking articles, and contribute to the ongoing dialogue in this vital discipline.